Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 11/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGAV | P06756 | 2/20 | 0.41 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.41 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6774132 | 1.00 | GPR139 (0.44) | GPR139ITGB3ITGAVTAOK1TAOK3 | |
| SCHEMBL6776891 | 0.91 | ITGB3 (0.47) | GPR139ITGB3ITGAVTAOK1TAOK3 | |
| SCHEMBL6776895 | 0.91 | ITGB3 (0.47) | GPR139ITGB3ITGAVTAOK1TAOK3 | |
| SCHEMBL6774133 | 0.84 | TP53 (0.45) | GPR139ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL6779624 | 0.83 | GPR139 (0.48) | GPR139ITGB3ITGAVTAOK1TAOK3 | |
| SCHEMBL6779632 | 0.83 | GPR139 (0.48) | GPR139ITGB3ITGAVTAOK1TAOK3 | |
| SCHEMBL3839471 | 0.82 | GPR139 (0.47) | GPR139ITGB3ITGAVTAOK1TAOK3 | |
| SCHEMBL6778751 | 0.82 | GPR139 (0.47) | GPR139ITGB3ITGAVTAOK1TAOK3 | |
| SCHEMBL6773424 | 0.82 | ITGB3 (0.49) | GPR139ITGB3ITGAVTAOK1TAOK3 | |
| SCHEMBL6773427 | 0.82 | ITGB3 (0.49) | GPR139ITGB3ITGAVTAOK1TAOK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |